Physician profile
Suzanne E Mcgee
NPI 1144663451
$997.66
in general payments reported to CMS, 2019-2025
16 companies · $40.02 in 2025
The $40.02 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $346 · 2024: $611 · 2025: $40.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.79 | 2023-2024 | |
| Lilly USA, LLC | $150.62 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $91.70 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $80.70 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $74.50 | 2024-2025 | Auvelity, Symbravo |
| Pfizer INC. | $61.79 | 2023-2024 | |
| Amgen INC. | $46.64 | 2023-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $40.43 | 2023-2024 | Verquvo, Gardasil, Gardasil 9 |
| Abbott Laboratories | $37.89 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $30.61 | 2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $22.31 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $16.13 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $14.98 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.83 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $13.02 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $12.72 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.